Compare · MASI vs NRXS
MASI vs NRXS
Side-by-side comparison of Masimo Corporation (MASI) and Neuraxis Inc. (NRXS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MASI and NRXS operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MASI is the larger of the two at $9.42B, about 111.9x NRXS ($84.2M).
- Over the past year, MASI is up 7.2% and NRXS is up 175.9% - NRXS leads by 168.8 points.
- MASI has hit the wire 2 times in the past 4 weeks while NRXS has been quiet.
- MASI has more recent analyst coverage (24 ratings vs 0 for NRXS).
- Company
- Masimo Corporation
- Neuraxis Inc.
- Price
- $179.96+0.00%
- $6.76+1.35%
- Market cap
- $9.42B
- $84.2M
- 1M return
- +0.93%
- -18.36%
- 1Y return
- +7.16%
- +175.92%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- AMEX
- IPO
- 2007
- 2023
- News (4w)
- 2
- 0
- Recent ratings
- 24
- 0
Masimo Corporation
Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. The company offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; O3 regional oximetry for tissue oxygen saturation measurement; and hemodynamic monitoring solutions. Its Masimo Hospital Automation platform includes Patient SafetyNet, Patient SafetyNet surveillance, Kite, UniView, Replica, UniView : 60, and MyView. The company offers coronavirus-2019 response and telehealth solutions; connectivity devices; and nasal high flow ventilation and neuromodulation solutions. The company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, physician offices, long term care facilities, veterinarians, and consumers; and non-medical/consumer products through e-commerce site, masimopersonalhealth.com. Incorporated in 1989, the company is headquartered in Irvine, California.
Latest MASI
- Sirius XM Holdings Set to Join S&P MidCap 400
- SEC Form SD filed by Masimo Corporation
- SEC Form SCHEDULE 13G filed by Masimo Corporation
- SEC Form 10-Q filed by Masimo Corporation
- Director Scannell Timothy J converted options into 1,225 shares, increasing direct ownership by 89% to 2,608 units (SEC Form 4)
- Director Lane Wendy E converted options into 1,225 shares, increasing direct ownership by 89% to 2,608 units (SEC Form 4)
- Chairman of the Board Brennan Michelle converted options into 1,225 shares, increasing direct ownership by 17% to 8,543 units (SEC Form 4)
- Chief Human Resources Officer Hellmann Elisabeth A converted options into 335 shares and covered exercise/tax liability with 121 shares (SEC Form 4) to satisfy tax liability
- Masimo Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits
- Masimo Shareholders Approve Acquisition by Danaher
Latest NRXS
- NeurAxis Reports Record First Quarter 2026 Financial Results Driven by 80% Year Over Year Revenue Growth
- SEC Form 10-Q filed by Neuraxis Inc.
- NeurAxis to Host First Quarter 2026 Results and Business Update Call on Tuesday, May 12, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by Neuraxis Inc.
- Director Aharon Gil was granted 234,221 shares, increasing direct ownership by 57% to 33,902 units (SEC Form 4)
- SEC Form DEFA14A filed by Neuraxis Inc.
- SEC Form DEF 14A filed by Neuraxis Inc.
- Neuraxis Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- NeurAxis Expands Payer Coverage with Four New Medical Policies
- Neuraxis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition